Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251844 · ClinicalTrials.gov registry record · NA
The Effectiveness of Email Alerting on Reducing Employees' Unauthorized Access to Protected Health Information
A NA study of Unauthorized Data Access, sponsored by Protenus.
- Completed
- Registry status
- NA
- Development phase
- 444
- Enrollment target
- 1
- Study location
NCT05251844 is a NA study of Unauthorized Data Access that has completed, run by Protenus. The registered enrollment target is 444 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05251844, a NA study of Unauthorized Data Access, has completed, sponsored by Protenus.
- COMPLETED
- Registry status
- NA
- Development phase
- 444 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the effectiveness of email warnings on reducing repeated unauthorized access to Protected Health Information (PHI), a randomized trial was conducted in a large academic medical center to understand the effectiveness of email warning on reducing repeated unauthorized access to PHI.
Conditions Studied
Interventions
- OTHER receiving an email
Study Locations (1)
Maryland
- Protenus, Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2021-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05251844
The ClinicalTrials.gov registry entry for NCT05251844 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protenus, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unauthorized Data Access appearing as the primary indexed condition, and to 1 intervention - of which receiving an email is the first listed.
NCT05251844 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05251844 about?
NCT05251844 is a clinical study titled "The Effectiveness of Email Alerting on Reducing Employees' Unauthorized Access to Protected Health Information". To assess the effectiveness of email warnings on reducing repeated unauthorized access to Protected Health Information (PHI), a randomized trial was conducted in a large academic medical center to understand the effectiveness of email warning on reducing repeated unauthorized access to PHI.
What is the current status of trial NCT05251844?
This trial is currently completed. It is a NA study. The enrollment target is 444 participants. The study started on 2018-01-01. Estimated completion is 2021-09-30.
What conditions does trial NCT05251844 study?
This clinical trial studies the following conditions: Unauthorized Data Access.
What interventions are being tested in trial NCT05251844?
The interventions under investigation include: receiving an email (OTHER).
Who is sponsoring clinical trial NCT05251844?
This trial is sponsored by Protenus, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05251844 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.